Longeveron Inc.

LGVN Healthcare Biotechnology

Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.18%, EPS grew 42.4% and free cash flow fell 49.1%, each against the same quarter a year earlier.

1.39 0.11 −7.33%
Market cap
$4.8M
P/E
0.0×
Fwd P/E
−1.1×
Dividend yield
—
F-score
3/9
Altman Z
−24.10
Beneish M
−3.83
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
9.59 7.42 21.20 18.58
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(2.73) (1.68) (5.90) (3.90)
P/B ratio
1.38 1.57 1.61 2.12
EV/Sales
3.73 3.68 8.88 10.75
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(0.31) (0.23) (0.57) (0.61)
Current Ratio
2.09 1.33 3.88 2.63
Net Debt/EBITDA
1.31 0.88 3.31 1.69
Debt/Equity
0.00 0.03 0.05 0.00
Earnings Yield
(39.24%) (252.96%) (108.65%) (140.83%)
Free Cash Flow Yield
(126.10%) (216.33%) (72.97%) (94.48%)
Free Cash Flow per Share
(2.82) (3.05) (1.77) (1.83)
Book value per Share
5.42 3.23 6.47 3.32
Free Cash Flow
(5.17) (5.36) (4.39) (5.76)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates